Literature DB >> 33210981

Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next?

Hidekazu Suzuki1, Hideki Mori2.   

Abstract

Year:  2021        PMID： 33210981      PMCID： PMC8262618          DOI： 10.1177/2050640620975357

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN： 2050-6406            Impact factor:   4.623


× No keyword cloud information.
  9 in total

1.  Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.

Authors:  P Malfertheiner; F Megraud; C A O'Morain; J P Gisbert; E J Kuipers; A T Axon; F Bazzoli; A Gasbarrini; J Atherton; D Y Graham; R Hunt; P Moayyedi; T Rokkas; M Rugge; M Selgrad; S Suerbaum; K Sugano; E M El-Omar
Journal:  Gut       Date:  2016-10-05       Impact factor: 23.059

2.  CAPZA1 determines the risk of gastric carcinogenesis by inhibiting Helicobacter pylori CagA-degraded autophagy.

Authors:  Hitoshi Tsugawa; Hideki Mori; Juntaro Matsuzaki; Akira Sato; Yoshimasa Saito; Masaya Imoto; Makoto Suematsu; Hidekazu Suzuki
Journal:  Autophagy       Date:  2018-09-10       Impact factor: 16.016

3.  Helicobacter  pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy.

Authors:  Sotirios D Georgopoulos; Vasilios Papastergiou; Stylianos Karatapanis
Journal:  Gastroenterol Res Pract       Date:  2012-06-19       Impact factor: 2.260

Review 4.  World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.

Authors:  Hidekazu Suzuki; Hideki Mori
Journal:  J Gastroenterol       Date:  2017-11-14       Impact factor: 7.527

5.  Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients.

Authors:  Hideki Mori; Hidekazu Suzuki; Fumio Omata; Tatsuhiro Masaoka; Daisuke Asaoka; Kohei Kawakami; Shigeaki Mizuno; Naoto Kurihara; Akihito Nagahara; Nobuhiro Sakaki; Masayoshi Ito; Yo Kawamura; Masayuki Suzuki; Yuji Shimada; Hitoshi Sasaki; Takeshi Matsuhisa; Akira Torii; Toshihiro Nishizawa; Tetsuya Mine; Toshifumi Ohkusa; Takashi Kawai; Kengo Tokunaga; Shin'ichi Takahashi
Journal:  Therap Adv Gastroenterol       Date:  2019-07-04       Impact factor: 4.409

6.  Neutrophil-activating Protein Polymorphism of Helicobacter pylori Determines the Host Risk of Dyspepsia.

Authors:  Juntaro Matsuzaki; Hitoshi Tsugawa; Yuki Kashiwazaki; Hideki Mori; Yuta Yamamoto; Hisako Kameyama; Tatsuhiro Masaoka; Takanori Kanai; Hidekazu Suzuki
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-05-18

Review 7.  Update on quinolone-containing rescue therapies for Helicobacter pylori infection.

Authors:  Hideki Mori; Hidekazu Suzuki
Journal:  World J Gastroenterol       Date:  2020-04-21       Impact factor: 5.742

8.  Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.

Authors:  Sho Suzuki; Takuji Gotoda; Chika Kusano; Hisatomo Ikehara; Ryoji Ichijima; Motoki Ohyauchi; Hirotaka Ito; Masashi Kawamura; Yohei Ogata; Masahiko Ohtaka; Moriyasu Nakahara; Koichi Kawabe
Journal:  Gut       Date:  2020-01-08       Impact factor: 23.059

9.  Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2017-10-08       Impact factor: 4.623
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.